Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of TGTX-101 for the treatment of GM2-Gangliosidosis

Trial Profile

Phase I/II study of TGTX-101 for the treatment of GM2-Gangliosidosis

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TSHA 101 (Primary)
  • Indications GM2 gangliosidoses
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Mar 2021 New trial record
    • 03 Mar 2021 According to a Taysha Gene Therapies media release, the company expects to submit an Investigational New Drug (IND) application in the U.S. in the second half of 2021 and initiate this in the 2H 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top